External genital and perianal warts (EGW) are caused by a virus called human papillomavirus (HPV). HPV is the most common infection passed from one person to another during sex.
Photo for illustrative purposes only. Not actual patients.
80%
of people who have sex get HPV at some point in their lives in the US
Up to 360,000 women and men have EGW every year in the US
About 1 in 100 adults who have sex has EGW at any given time in the US
Small, skin-colored spots, either raised or flat, that may have a cauliflower-like shape
In women: on the vulva, vagina, cervix, groin, and around the anus
In men: on the penis, scrotum, groin, and around the anus
If you have oral sex: in the mouth or throat
Well, sometimes no. EGW can stay the same size or clear up on their own, but they can also increase in number and size. Why take a chance when you may be able to get rid of them sooner?
Most people need treatment to get rid of EGW, even though treatment does not get rid of the HPV infection.
Your first instinct may be to skip the doctor and pick up some over-the-counter wart removers. Don't do it! They're just not made for your genital area and can cause even more pain and irritation. Leave it up to your doctor to tell you which treatment is right for you.
Treatment |
What it does |
How to apply |
How it's dosed |
|---|---|---|---|
Sinecatechins |
Helps clear EGW |
3x/day |
Daily for up to 16 weeks |
There are also things your dermatologist can do during your office visit. Your doctor will help decide what's right for you.
Are you pregnant? Call your doctor right away if you're pregnant and you or your partner has EGW. Your doctor will decide whether or not to treat your EGW.
EGW=external genital and perianal warts
Do not use VEREGEN® (sinecatechins) Ointment, 15% if you are allergic to any ingredient in this product. Do not use VEREGEN® Ointment, 15% for warts in the vagina, cervix, or inside the anus. Avoid contact with your eyes, nostrils and mouth while ointment is on your finger(s).
Avoid use of VEREGEN® on open wounds. Do not expose skin that has been treated with VEREGEN® to the sunlight, sunlamps or tanning beds. Tell your doctor if you are using any other type of skin product on the area to be treated. Avoid sexual contact (genital, anal or oral) when VEREGEN® Ointment, 15% is on your genital or perianal skin. If you do choose to have sexual contact, you must wash off the ointment carefully before having protected sexual contact as the ointment may weaken condoms and vaginal diaphragms.
Be sure to tell the doctor if you have a weak immune system, if you are pregnant or nursing a baby, or if you have used VEREGEN® before. Avoid using this product in patients younger than 18 years of age or for longer than 16 weeks. If your warts do not go away or come back after treatment contact your doctor.
The most common side effects with VEREGEN® Ointment, 15% are local skin and application site reactions including (incidence ≥20%): redness, itching, burning, pain, sores, swelling, hard spots, and rash with blisters.
For more information, consult your healthcare professional.
Please see full Prescribing Information for VEREGEN®.
You are encouraged to report negative side effects of prescription drugs to the Food and Drug Administration (FDA). Please visit www.fda.gov/medwatch or call 1-800-FDA-1088.
VEREGEN® is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
Do not use VEREGEN® (sinecatechins) Ointment, 15% if you are allergic to any ingredient in this product. Do not use VEREGEN® Ointment, 15% for warts in the vagina, cervix, or inside the anus. Avoid contact with your eyes, nostrils and mouth while ointment is on your finger(s).
Avoid use of VEREGEN® on open wounds. Do not expose skin that has been treated with VEREGEN® to the sunlight, sunlamps or tanning beds. Tell your doctor if you are using any other type of skin product on the area to be treated. Avoid sexual contact (genital, anal or oral) when VEREGEN® Ointment, 15% is on your genital or perianal skin. If you do choose to have sexual contact, you must wash off the ointment carefully before having protected sexual contact as the ointment may weaken condoms and vaginal diaphragms.
Be sure to tell the doctor if you have a weak immune system, if you are pregnant or nursing a baby, or if you have used VEREGEN® before. Avoid using this product in patients younger than 18 years of age or for longer than 16 weeks. If your warts do not go away or come back after treatment contact your doctor.
The most common side effects with VEREGEN® Ointment, 15% are local skin and application site reactions including (incidence ≥20%): redness, itching, burning, pain, sores, swelling, hard spots, and rash with blisters.
For more information, consult your healthcare professional.
Please see full Prescribing Information for VEREGEN®.
You are encouraged to report negative side effects of prescription drugs to the Food and Drug Administration (FDA). Please visit www.fda.gov/medwatch or call 1-800-FDA-1088.
VEREGEN® is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
This section includes technical information. If you're a US healthcare provider, click "Continue." Otherwise, click "Return" to keep reading the patient site.
ANI Pharmaceuticals is not responsible for the privacy policy, the content, or the accuracy of any websites accessed through a link on the veregen.com site. A link to other websites does not constitute an endorsement of ANI Pharmaceuticals or the linked site, its products, or services.
The browser window or tab for veregen.com will remain open. To return to veregen.com at any time, close this tab or window.
Photo provided with permission from Silvio Tatti, MD, PhD, First Chair Gynecology, Hospital de Clinicas, Buenos Aires, Argentina.
Photo provided with permission from Silvio Tatti, MD, PhD, First Chair Gynecology, Hospital de Clinicas, Buenos Aires, Argentina.
Proto provided with permission from Eggert Stockfleth, Director of the Skin Cancer Center, University Hospital Charite, Berlin, Germany.
Photo provided with permission from Theodore Rosen, MD, Professor of Dermatology, Baylor College of Medicine, Houston, Texas.
Photo provided with permission from Silvio Tatti, MD, PhD, First Chair Gynecology, Hospital de Clinicas, Buenos Aires, Argentina.
Photo provided with permission from Silvio Tatti, MD, PhD, First Chair Gynecology, Hospital de Clinicas, Buenos Aires, Argentina.
Proto provided with permission from Eggert Stockfleth, Director of the Skin Cancer Center, University Hospital Charite, Berlin, Germany.
Photo provided with permission from Theodore Rosen, MD, Professor of Dermatology, Baylor College of Medicine, Houston, Texas.